Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal® vet, Phenoleptil®) in dogs

BACKGROUND: In human medicine, adverse outcomes associated with switching between bioequivalent brand name and generic antiepileptic drug products is a subject of concern among clinicians. In veterinary medicine, epilepsy in dogs is usually treated with phenobarbital, either with the standard brand...

Descripción completa

Detalles Bibliográficos
Autores principales: Bankstahl, Marion, Bankstahl, Jens P, Löscher, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853146/
https://www.ncbi.nlm.nih.gov/pubmed/24107313
http://dx.doi.org/10.1186/1746-6148-9-202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853146/
https://www.ncbi.nlm.nih.gov/pubmed/24107313
http://dx.doi.org/10.1186/1746-6148-9-202

Ejemplares similares